Radijum-223 hlorid
| Klinički podaci | |
|---|---|
| Prodajno ime | Alpharadin, Xofigo |
| Drugs.com | chloride.html Monografija |
| Način primene | Intravenozno |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 11,4 dana |
| Identifikatori | |
| CAS broj | 444811-40-9  |
| ATC kod | None |
| DrugBank | DB08913 |
| UNII | RJ00KV3VTG |
| ChEBI | CHEBI:74895 |
| Hemijski podaci | |
| Formula | 223RaCl2 |
| Molarna masa | 296,91 |
Radijum-223 hlorid je izotop radijuma sa 11,4-dana dugim poluživotom, u kontrastu sa uobičajenim izotopom radijum-226, čiji poluživot je 1601 godina. Glavna primena radijuma-223 je kao radiofarmaceutik za tretiranje metastatičkih kancera kostiju. Ovaj oblik primene se bazira na njegovoj hemijskoj sličnosti sa kalcijumom, i kratkim opsegom njegove alfa radijacije.[1][2][3][4][5]
Reference[уреди | уреди извор]
- ^ Suominen MI, Rissanen JP, Kakonen R, Fagerlund KM, Alhoniemi E, Mumberg D, Ziegelbauer K, Halleen JM, Kakonen SM, Scholz A: Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis. J Natl Cancer Inst. 2013 Jun 19;105(12):908-16. doi: 10.1093/jnci/djt116. Epub 2013 May 16. PMID 23682134
- ^ Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernas B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B, Bruland OS: Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007 Jul;8(7):587-94. PMID 17544845
- ^ Bruland OS, Nilsson S, Fisher DR, Larsen RH: High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6250s-6257s. PMID 17062709
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
Literatura[уреди | уреди извор]
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
